ArticleHemaSphere2025

A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia.

Wei-Ying Jen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.